Medical Oncologist, Dr. Nicholas Vogelzang, Presented Research on a New FDA Approved Cancer Therapy to the American Society of Clinical Oncology
Medical Oncologist, Dr. Nicholas Vogelzang recently presented data on the drug Xofigo at the annual meeting of the American Society of Clinical Oncology.
Online, July 11, 2013 (Newswire.com) - Medical oncologist at Comprehensive Cancer Centers of Nevada (CCCN), Dr. Nicholas Vogelzang, presented data from a recently FDA approved cancer therapy, Xofigo at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in June.
Dr. Vogelzang presented data from a clinical research study on the safety and efficiency of the drug Radium-223 (commercially known as Xofigo) in patients with castration resistant prostate cancer (CRPC) and symptomatic bone metastases. The study, which included 921 randomized participants, was designed as liquid radiation to attack prostate cancer cells that have grown in patients' bones. According to Dr. Vogelzang, "this drug improved pain, it improved quality of life, and it is very easy on the patient."
Dr. Vogelzang, who has been involved with prostate cancer research for more than 30 years, ensured the clinical research study became available in Nevada. He and radiation oncologists at CCCN, Farzaneh Farzin, MD and Michael J. Anderson, MD, tested the drug, and after analyzing the data reported multiple benefits to patients. Overall, the drug increased quality of life while reducing the need for pain medication.
Las Vegas was one of two cities in the United States treating prostate cancer patients during the research study. According to the CCCN oncologists, the drug has few or less severe side effects compared to other treatments. Many patients even reported feeling normal again after receiving Xofigo.
To learn more about Dr. Vogelzang, the other qualified oncologists at Comprehensive Cancer Centers of Nevada, or clinical research studies in Las Vegas visit http://www.cccnevada.com/ or call (702) 952-3350.